Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Drug Developer Kadmon Skids Following Weak Demand for IPO

By AP | July 28, 2016

NEW YORK (AP) — Shares of drug developer Kadmon Holdings tumbled Wednesday after its initial public offering priced far below the company’s estimates.

Kadmon said its offering of 6.25 million shares priced at $12 a share, raising $75 million in total. The company originally planned to sell 5.6 million shares for $16 to $20 each, which would have raised at least $89 million before expenses and discounts.

Kadmon Holdings Inc. shares closed down $2.30, or 19 percent, at $9.70.

The New York company is studying potential treatments for diseases including psoriasis and cancer. Kadmon was founded in 2010 by Samuel Waksal, who was its chairman and CEO while it was a private company, and its current president and CEO is his brother Harlan Waksal. Both were formerly involved with thedrug developer ImClone Systems, and in 2002 Samuel Waksal plead guilty to securities and bank fraud charges that stemmed from an in insider trading investigation. He spent almost six years in prison, and ImClone investor Martha Stewart went to prison as a result of the same investigation. Samuel Waksal is barred from serving as an executive of a publicly traded company as a result.

Harlan Waksal was not implicated in that investigation. He later resigned from ImClone, which was bought by Eli Lilly & Co. in 2008.

Samuel Waksal resigned from the company in February and Kadmon says it does not expect him to return as an employee or consultant or in any other capacity. He is entitled to $3 million in severance from the company over the next few years and could get more than $20 million in additional payments based on Kadmon’s valuation, the performance of its drug candidates, and other items.

The company said it will use the proceeds of its IPO to conduct clinical trials of its drugs and do other research, and to repay a $3 million loan from Harlan Waksal.

Its stock is listed on the New York Stock Exchange under the ticker symbol “KDMN.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE